255 related articles for article (PubMed ID: 36511878)
1. Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A.
Van Lent J; Vendredy L; Adriaenssens E; Da Silva Authier T; Asselbergh B; Kaji M; Weckhuysen S; Van Den Bosch L; Baets J; Timmerman V
Brain; 2023 Jul; 146(7):2885-2896. PubMed ID: 36511878
[TBL] [Abstract][Full Text] [Related]
2. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
[TBL] [Abstract][Full Text] [Related]
3. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
4. Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.
Intisar A; Woo H; Kang HG; Kim WH; Shin HY; Kim MY; Kim YS; Mo YJ; Lee YI; Kim MS
Biosens Bioelectron; 2023 Mar; 224():115055. PubMed ID: 36630746
[TBL] [Abstract][Full Text] [Related]
5. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
[TBL] [Abstract][Full Text] [Related]
6. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
[TBL] [Abstract][Full Text] [Related]
7. Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs.
Shi L; Huang L; He R; Huang W; Wang H; Lai X; Zou Z; Sun J; Ke Q; Zheng M; Lu X; Pei Z; Su H; Xiang AP; Li W; Yao X
Stem Cell Reports; 2018 Jan; 10(1):120-133. PubMed ID: 29276154
[TBL] [Abstract][Full Text] [Related]
8. Regulation of myelin-specific gene expression. Relevance to CMT1.
Kamholz J; Awatramani R; Menichella D; Jiang H; Xu W; Shy M
Ann N Y Acad Sci; 1999 Sep; 883():91-108. PubMed ID: 10586235
[TBL] [Abstract][Full Text] [Related]
9. PMP22 expression in dermal nerve myelin from patients with CMT1A.
Katona I; Wu X; Feely SM; Sottile S; Siskind CE; Miller LJ; Shy ME; Li J
Brain; 2009 Jul; 132(Pt 7):1734-40. PubMed ID: 19447823
[TBL] [Abstract][Full Text] [Related]
10. Generation of one induced pluripotent stem cell line JUCGRMi004-A from a Charcot-Marie-Tooth disease type 1A (CMT1A) patient with PMP22 duplication.
Liu X; Ishikawa KI; Hattori N; Akamatsu W
Stem Cell Res; 2024 Jun; 77():103401. PubMed ID: 38537501
[TBL] [Abstract][Full Text] [Related]
11. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.
Stavrou M; Kagiava A; Choudury SG; Jennings MJ; Wallace LM; Fowler AM; Heslegrave A; Richter J; Tryfonos C; Christodoulou C; Zetterberg H; Horvath R; Harper SQ; Kleopa KA
J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35579942
[TBL] [Abstract][Full Text] [Related]
12. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
[TBL] [Abstract][Full Text] [Related]
13. Charcot-Marie-Tooth disease and related inherited neuropathies.
Murakami T; Garcia CA; Reiter LT; Lupski JR
Medicine (Baltimore); 1996 Sep; 75(5):233-50. PubMed ID: 8862346
[TBL] [Abstract][Full Text] [Related]
14. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
[TBL] [Abstract][Full Text] [Related]
15. Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages.
Hanemann CO; Gabreëls-Fasten AA; Müller HW; Stoll G
Brain; 1996 Oct; 119 ( Pt 5)():1461-9. PubMed ID: 8931571
[TBL] [Abstract][Full Text] [Related]
16. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
[TBL] [Abstract][Full Text] [Related]
17. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
[TBL] [Abstract][Full Text] [Related]
18. Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development.
Lopez-Anido C; Poitelon Y; Gopinath C; Moran JJ; Ma KH; Law WD; Antonellis A; Feltri ML; Svaren J
Hum Mol Genet; 2016 Jul; 25(14):3055-3069. PubMed ID: 27288457
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.
Hanemann CO; Müller HW
Trends Neurosci; 1998 Jul; 21(7):282-6. PubMed ID: 9683317
[TBL] [Abstract][Full Text] [Related]
20. AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells.
Yoshioka Y; Taniguchi JB; Homma H; Tamura T; Fujita K; Inotsume M; Tagawa K; Misawa K; Matsumoto N; Nakagawa M; Inoue H; Tanaka H; Okazawa H
Commun Med (Lond); 2023 Nov; 3(1):170. PubMed ID: 38017287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
